Evidence map›Paper›PMID 41625911›Full record

ReviewCureus2025

The Present and Future of Pain Management in Patients With Chronic Kidney Disease: A Narrative Review.

Igor Wilderman, Francesca Sarzetto, Budvin Wijetillake, Sydney Verdun

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Igor WildermanPain Management, Wilderman Medical Clinic, Thornhill, CAN.
Francesca SarzettoPain Management, Canadian Centre for Clinical Trials, Thornhill, CAN.
Budvin WijetillakeResearch, Canadian Centre for Clinical Trials, Thornhill, CAN.
Sydney VerdunResearch, Canadian Centre for Clinical Trials, Thornhill, CAN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is an increasingly common ailment, greatly affecting the quality of life, morbidity, and mortality of the population. In addition, more than half of patients with CKD experience chronic pain, mostly of nociceptive or neuropathic origin, and physicians frequently have to find a difficult balance between safety and efficacy to control it. The altered metabolism and renal excretion in patients with CKD modify the pharmacokinetics and pharmacodynamics of several analgesic drugs, making this population more prone to side effects and lower efficacy, since the doses often need to be reduced. This narrative review describes the current pharmacological approaches for nociceptive and neuropathic pain, and emerging alternatives, such as cannabinoids and low-dose naltrexone. We also describe the current knowledge on anesthesia, perioperative and acute pain management, and injectables, including ketamine and corticosteroids (intra-articular and epidural). In the variable and possibly deteriorating clinical context of CKD, this review shows that pain management needs to be individualized and carefully discussed with the patient; close monitoring is also necessary to adjust the treatment and obtain effective pain control while minimizing the risk.

Indexed as

analgesiaanesthesiachronic kidney diseasechronic painpain management

Identifiers

PMID41625911
PMCPMC12857586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.